We are live on ! Find out more
BVF Inc

BVF Inc Portfolio holdings

AUM $3.91B Turnover 15.22%
1-Year Est. Return 304.52%
This Fund
S&P 500
This Quarter Est. Return
-1.19%
1 Year Est. Return
+304.52%
3 Year Est. Return
+591.72%
5 Year Est. Return
+1,391.93%
10 Year Est. Return
+28,184.7%
AUM
$632M
AUM Growth
-$12.8M
Cap. Flow
+$278K
Cap. Flow %
0.04%
Top 10 Hldgs %
85.21%
Holding
32
New
4
Increased
11
Reduced
4
Closed
3
Avg Time Held Equity + Options
0.7 years
Top 10 Avg Time Held Equity + Options
0.8 years
Top 20 Avg Time Held Equity + Options
0.7 years
Avg Time Held Equity only
0.7 years
Top 10 Avg Time Held Equity only
0.8 years
Top 20 Avg Time Held Equity only
0.7 years

Top Buys

Rank Stock Value
1
ARRY icon
Array Biopharma Inc
ARRY
+$25.8M
2
RCPT
RECEPTOS INC COM STK (DE)
RCPT
+$15.9M
3
CYTK icon
Cytokinetics
CYTK
+$7.39M
4
TBRA
Tobira Therapeutics, Inc. Common Stock
TBRA
+$6.41M
5
ACHV icon
Achieve Life Sciences
ACHV
+$4.82M

Top Sells

Rank Stock Value
1
LGND icon
Ligand Pharmaceuticals
LGND
+$13.2M
2
RIGL icon
Rigel Pharmaceuticals
RIGL
+$10M
3
OMED
OncoMed Pharmaceuticals, Inc.
OMED
+$4.05M
4
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
+$1.43M
5
PTN icon
Palatin Technologies
PTN
+$1.37M

Sector Composition

Rank Sector Weight
1 Healthcare 86.28%
2 Miscellaneous 13.72%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow Held Since
IRWD icon
1
Ironwood Pharmaceuticals
IRWD
$775M
$141M 22.33%
10,995,437
-112,349
-1% -$1.22M
2013 Q2
4 quarters
LGND icon
2
Ligand Pharmaceuticals
LGND
$6.28B
$118M 18.65%
3,034,676
-325,879
-10% -$13.2M
2013 Q2
4 quarters
ARRY icon
3
DELISTED
Array Biopharma Inc
ARRY
$67.1M 10.61%
14,715,786
+6,228,859
+73% +$25.8M
2013 Q2
4 quarters
CCXI icon
4
DELISTED
ChemoCentryx, Inc.
CCXI
$47.9M 7.57%
8,181,816
+385,300
+5% +$2.16M
2013 Q2
4 quarters
RCPT
5
DELISTED
RECEPTOS INC COM STK (DE)
RCPT
$38.8M 6.13%
910,600
+459,800
+102% +$15.9M
2013 Q2
4 quarters
CASC
6
DELISTED
Cascadian Therapeutics, Inc.
CASC
$31.9M 5.05%
1,643,046
+142,750
+10% +$2.52M
2013 Q2
4 quarters
GYRE icon
7
Gyre Therapeutics
GYRE
$493M
$30M 4.75%
8,451
+614
+8% +$2M
2013 Q2
4 quarters
FPRX
8
DELISTED
Five Prime Therapeutics, Inc.
FPRX
$19.5M 3.08%
1,253,000
+117,000
+10% +$1.68M
2013 Q4
2 quarters
OMED
9
DELISTED
OncoMed Pharmaceuticals, Inc.
OMED
$19.2M 3.04%
825,647
-164,131
-17% -$4.05M
2013 Q3
3 quarters
TBRA
10
DELISTED
Tobira Therapeutics, Inc. Common Stock
TBRA
$17.7M 2.8%
289,677
+105,334
+57% +$6.41M
2013 Q3
3 quarters
QLTI icon
11
DELISTED
QLT Inc
QLTI
$14.6M 2.32%
2,370,263
– –
2013 Q2
4 quarters
TRVN icon
12
DELISTED
Trevena, Inc.
TRVN
$6.32M 1%
1,790
+1,230
+220% +$3.84M
2014 Q1
1 quarter
CYTK icon
13
Cytokinetics
CYTK
$7.68B
$6.3M 1%
1,317,000
+1,211,295
+1,146% +$7.39M
2013 Q2
4 quarters
ARQL
14
DELISTED
Arqule Inc
ARQL
$4.84M 0.77%
3,124,887
+675,500
+28% +$1.06M
2013 Q2
4 quarters
EXEL icon
15
Exelixis
EXEL
$17.5B
$3.39M 0.54%
+1,000,000
New +$3.45M
2014 Q2
0 quarters
ACHV icon
16
Achieve Life Sciences
ACHV
$699M
$3.22M 0.51%
+392
New +$4.82M
2014 Q2
0 quarters
BLRX icon
17
BioLineRX
BLRX
$7.87M
$3.12M 0.49%
2,502
+1,169
+88% +$1.46M
2014 Q1
1 quarter
KBIO
18
DELISTED
KALOBIOS PHARMACEUTICALS INC COM STK NEW (DE)
KBIO
$2.65M 0.42%
+145,250
New +$2.49M
2014 Q2
0 quarters
ANTH
19
DELISTED
Anthera Pharmaceuticals, Inc.
ANTH
$1.9M 0.3%
69,953
– –
2013 Q2
4 quarters
AKAO
20
DELISTED
Achaogen Inc
AKAO
$1.74M 0.28%
125,000
– –
2014 Q1
1 quarter
QURE icon
21
uniQure
QURE
$1.6B
$1.7M 0.27%
+125,000
New +$1.36M
2014 Q2
0 quarters
PTN icon
22
Palatin Technologies
PTN
$12.9M
$1.6M 0.25%
1,289
-959
-43% -$1.37M
2013 Q2
4 quarters
BIND
23
DELISTED
BIND THERAPEUTICS INC
BIND
$1.53M 0.24%
116,000
– –
2013 Q4
2 quarters
RGLS icon
24
DELISTED
Regulus Therapeutics
RGLS
$1.49M 0.24%
1,542
– –
2013 Q2
4 quarters
SPHS
25
DELISTED
Sophiris Bio, Inc.
SPHS
$1.34M 0.21%
600,000
– –
2013 Q3
3 quarters
1
2

Similar funds

LFCM
Long Focus Capital Management San Juan, Puerto Rico $3.91B AUM 12.68% 1-Year Est. Return
DME Capital Management
DME Capital Management New York $3.91B AUM 36.1% 1-Year Est. Return
GTCR LLC
GTCR LLC Chicago, Illinois $3.91B AUM 14.64% 1-Year Est. Return
AC
Anther Capital Hong Kong $3.91B AUM
Founders Fund Growth II Management
Founders Fund Growth II Management San Francisco, California $3.9B AUM
Saba Capital Management
Saba Capital Management New York $3.9B AUM 12.9% 1-Year Est. Return
Masters Capital Management
Masters Capital Management Atlanta, Georgia $3.9B AUM 50.88% 1-Year Est. Return
Champlain Investment Partners
Champlain Investment Partners Burlington, Vermont $3.89B AUM 16.15% 1-Year Est. Return

BVF Inc's Q2 2014 Portfolio in Review

As of Q2 2014, BVF Inc held 32 positions worth $632M, down 2% from $645M the previous quarter. Its ten largest holdings account for 85% of the portfolio.

BVF Inc's Q2 2014 filing shows 4 new, 11 increased, 4 reduced and 3 closed positions. Its largest new stake was Achieve Life Sciences: 392 shares worth $3.22M. The largest sale was Ligand Pharmaceuticals, an estimated $13.2M.

By sector, the portfolio is most concentrated in Healthcare at 86% of assets, up from 82% a quarter earlier, followed by Miscellaneous.

  • BVF Inc's largest Q2 2014 buy was Achieve Life Sciences: 392 shares worth $3.22M.
  • BVF Inc added most to Array Biopharma Inc in Q2 2014, an estimated $25.8M increase.
  • BVF Inc's biggest Q2 2014 reduction was Ligand Pharmaceuticals, cutting an estimated $13.2M.
  • BVF Inc fully exited Rigel Pharmaceuticals in Q2 2014, selling an estimated $10M.
  • BVF Inc's ten largest holdings make up 85% of its $632M portfolio in Q2 2014.
  • BVF Inc opened 4 new positions and closed 3 in Q2 2014.
  • BVF Inc's portfolio value fell 2% quarter-over-quarter to $632M.

Based on BVF Inc's 13F filing for Q2 2014, filed 14 Aug 2014.